Chitec Technology Co., Ltd. Overview
Chitec is a small, research-led Taiwanese maker of polymer and coating additives. Its products protect materials from light and heat (UV absorbers, hindered-amine light stabilisers, antioxidants), cure them with light (photoinitiators) or make them flame-resistant. With about TWD 1.7 billion of revenue in FY2025 and two plants in Hsinchu and Changhua (Changbin), it competes against BASF, Songwon, SI Group and a large field of Chinese producers by avoiding commodity grades and selling patented, regulation-ready molecules such as Chiguard GA403, R-455 and 9546 and Revonox 501 and 420V. It supports these with FDA, EFSA, REACH and TSCA registrations and flexible small-batch production. More than 90% of sales are exported through over 20 distributors. Customers increasingly value it as a non-China source. The 2026 agenda is to turn blue-light absorbers and optical-grade additives into the next growth leg, enter electronic and battery materials, and defend a gross margin that has slipped from 28% to about 23–24%.
Company's own description. The corporate website states that Chitec "specializes in the research and development of high-performance chemical additives for various industries, including electronics, automotive, aerospace, construction, packaging, and synthetic fibers", with major product lines of UV stabilisers, antioxidants, photoinitiators and flame retardants. Its registered business scope is the R&D, production and sale of UV absorbers and light stabilisers, photoinitiators, and antioxidants and other specialty chemicals. The corporate tagline is "We pursue difference, not numbers."
Independent characterisation. Chitec is a pure-play, single-segment specialty additives formulator and synthesiser. It designs molecules, scales them in multi-purpose batch plants in Taiwan, secures regulatory clearances (food contact, REACH, TSCA) and sells mainly through distributors to compounders, resin makers, coatings and ink formulators and film makers. It sits in the middle of the value chain: upstream are petrochemical intermediates (phenols, amines, triazine and benzotriazole precursors, phosphorus chemistry); downstream are plastics compounders, coating and ink houses and optical-film and lens makers; end-markets are automotive, construction, packaging, consumer electronics, textiles and fibres, and printing.
Revenue model. Revenue is essentially all product sales priced per kilogram. No subscription, licensing or service revenue is disclosed. A small historical element is toll or OEM manufacturing: the Changhua plant started in 2014 producing flame retardant FCX-210 for Teijin Chemical. In September 2026 management said supply-chain realignment is creating new "strategic cooperation and toll-manufacturing opportunities".
Mix. Per the 23 September 2026 investor conference, the 2026 product mix is UV absorbers and light stabilisers 60%, antioxidants 22.3%, photoinitiators 15.4% and flame retardants 1.6%.
Margin structure by line (management Q&A, September 2026, against a 1H2026 blended gross margin of 24.21%): antioxidants are above average, UV absorbers and light stabilisers slightly below average, and photoinitiators below average because of intense competition.
Customer types. Global coatings majors (PPG approved Chitec UV absorbers in 2001), imaging companies (Eastman Kodak 2002, Carestream 2008), chemical majors (DuPont Supplier Quality Award 2012 and 2013; Chimei co-patent 1999; Teijin OEM 2014), PET packaging converters, optical film and lens makers, PCB ink formulators and engineering-plastic compounders for consumer electronics.
End-market framing on the company website. Coatings (automotive, industrial, wood); UV/LED curing and printing; adhesives and sealants; plastics (automotive and transportation, building and construction, packaging, agriculture, consumer goods, textiles and fibres, electrical and electronics); optical coatings.
Strategy
Stated strategic themes. The website's motto is "We pursue difference, not numbers", with innovation framed as "Greener, Safer, Effective". At the September 2026 conference management described its edge as molecular design, innovation, customer solutions and flexible production planning, and said it does not take part in commodity price wars.
Initiatives in the last 24 months
Financial guidance. For 2027 management is "conservatively optimistic", aiming for near double-digit revenue growth. It declined to forecast gross margin because of inflation and raw-material costs, but intends to hold it near the 2026 level through mix upgrade and cost pass-through. No formal medium-term margin, ROE or capex targets are disclosed. No cost-reduction programme with numeric targets was identified.
ESG commitments. ISO 14064-1 greenhouse-gas inventory in place. No quantified emissions-reduction target was found.
Products & Services
Chitec publishes four product families and a product selector on its website, and released a "2026 Plastic Additives Catalog" on 11 May 2026. Pricing is not disclosed for any product.
A. Verified flagship and named products
B.
Services. Application and technical service (weathering and physical-property testing), regulatory dossiers, a distributor platform and e-book shelf, the "Chitec Focus" newsletter, and toll manufacturing. A Shanghai application laboratory is planned to open in 2027.
Pipeline (September 2026 conference and press): additional blue-light absorbers; optical-grade additives; cathode and anode binder resins, dispersants and electrolyte components for non-China energy-storage customers; processing aids for engineering plastics in consumer electronics, electric vehicles and humanoid robots. A third-party research note, unconfirmed by the company in sources retrieved, reports EUV photoresist-related monomers and a dedicated high-cleanliness electronic-grade line.
Product Portfolio
| Family / brand | Product | Description and capability | Target use | Year / status |
|---|---|---|---|---|
UV stabilisers (Chiguard) | Chiguard GA403 | Patented UV blocker; TSCA and REACH registered (2020); passed EFSA food-contact assessment (2026); China food-contact national standard applied for, expected 2027 | PET packaging for food, pharma and personal care; also cited among blue-light products | Patented 2020; EU food contact 2026 |
UV stabilisers (Chiguard) | Chiguard R-445 | Reactable (polymer-bound) UV absorber; global patents, TSCA/REACH | Coatings and polymers needing non-migrating UV protection | 2020 |
UV stabilisers (Chiguard) | Chiguard R-455 | Reactive/polymeric UV absorber technology; TCIA Product Innovation Award 2023; US invention patent June 2026; "2026 Innovative Material Award" September 2026 | High-durability coatings, optical and engineering plastics | 2023–2026 |
UV stabilisers (Chiguard) | Chiguard 9546 (BLA) | Blue-light absorber; Canadian notice of allowance July 2026; South Korean patent August 2026 | Wearables, automotive displays, AR-HUD and smart windshields, optical films, blue-cut lenses | Commercialising 2026 |
UV stabilisers | KB403 | Blue-light absorber named by management as in mass production | Blue-cut lenses, AR/VR displays, HUD | Mass production 2026 |
UV stabilisers (Chiguard) | Chiguard Wood Series | Light-stabiliser packages for wood coatings | Wood coatings | Featured September 2026 |
UV stabilisers | Anhydrous liquid additive series | Water-dispersible liquid additives without the storage and transport limits of emulsions | Waterborne coatings under VOC rules | Disclosed September 2026 |
Antioxidants (Revonox) | Revonox 501 | Patented broad-spectrum, high-efficiency antioxidant; TSCA and FDA cleared; DT New Materials award 2025 | Engineering plastics, polyolefins, food-contact uses | 2011 |
Antioxidants (Revonox) | Revonox 420V | Phenol-free antioxidant derived from palm oil; FDA approved | Packaging and sustainability-positioned applications | 2016 |
Antioxidants (Revonox) | Revonox 608 | Antioxidant grade; packaging updated July 2026 | Polymer processing stabilisation | Current |
Antioxidants (Revonox series) | PCR stabilisation packages | Positioned for oxidation and colour stability of post-consumer recyclate under EU PPWR | Recycled plastics | Promoted March 2026 |
Antioxidants (legacy) | Chinox 850 | Eco-friendly antioxidant for ABS, co-patented with Chimei | ABS resin | 1999 |
Antioxidants (legacy) | Trisphenol antioxidant | Proprietary antioxidant | Carestream medical X-ray film | 2008 |
Photoinitiators (Chivacure) | Chivacure TPO | Acylphosphine-oxide photoinitiator developed for optical-fibre coatings | Optical-fibre coatings, UV coatings and inks | 2000 |
Photoinitiators (R-gen) | R-gen 990 | Patented liquid photoinitiator for LED UV curing and black-ink systems | UV-LED inks, PCB inks, digital printing | 2019 |
Flame retardants (Zuran) | Zuran series | Environment-oriented, non-halogen flame retardants | Engineering plastics, electronics | Current; order pick-up noted 2H2025 |
Flame retardants (OEM) | FCX-210 | Toll production of Teijin Chemical's flame retardant at Changhua | Teijin (polycarbonate applications) | From 2014 |
| Family | Illustrative grades | Chemistry |
|---|---|---|
Chiguard UV absorbers | 234, 326, 328, 5530, 1064 | Benzotriazoles; hydroxyphenyl-triazine |
Chiguard HALS | 101, 770, 622, 944 | Hindered-amine light stabilisers (liquid, monomeric and oligomeric) |
Deox antioxidants | Deox 10, Deox 76, Deox 68 | Hindered phenolics and phosphite |
Chivacure photoinitiators | 184, 173, TPO-L, BMS, DETX, ITX, EPD | Free-radical initiators and amine synergists |
R-gen photoinitiators | Cationic sulfonium and iodonium grades | Cationic UV curing |
Financial Narrative
All figures are TWD million unless stated. Source: S&P Global Market Intelligence via StockAnalysis.com. Dividends per share are attributed to the earnings year and paid the following year.
6.1 Income statement
Revenue CAGR FY2021–FY2025 is about 3.4% (analyst calculation). FY2024 pre-tax income includes a TWD 14.38 million unusual charge.
Commentary. Revenue peaked at TWD 1,598 million in FY2022, fell 21% in the FY2023 destocking, and recovered to a record TWD 1,711 million in FY2025. Profit did not follow. Gross margin dropped 5.3 points in FY2025 to 22.97%, the lowest of the five years, and net income of TWD 106 million was the lowest of the period. Three things explain this: a shift toward UV stabilisers and China volume (both below-average margin), photoinitiator price competition, and a swing from a TWD 18.6 million currency gain to a TWD 5.8 million loss. The effective tax rate also rose to 28.7%.
6.2 Balance sheet (year-end)
Commentary. The 2022 listing raised TWD 186.5 million and moved the company from net debt to net cash. Net cash has since fallen from TWD 308 million (FY2023) to TWD 218 million (FY2025) and TWD 186 million at 30 June 2026, as capex, receivables and inventory absorbed cash. At 30 June 2026 total debt was TWD 241 million after more than TWD 130 million of long-term borrowing for the Taipei office, and PP&E had risen to TWD 585 million.
6.3 Cash flow
Commentary. Free cash flow has fallen every year, from TWD 277 million to TWD 21 million, as capex rose more than fivefold (Changbin warehouse and laboratory) and working capital grew with sales. In the twelve months to June 2026 free cash flow was negative TWD 43 million on capex of TWD 232 million, which includes the Taipei office. FY2025 dividends of TWD 84 million exceeded free cash flow and were funded from the cash balance.
6.4 Ratios
Interest coverage and the cash-conversion components are analyst calculations on year-end balances. Other ratios are as reported by S&P.
Commentary. Returns have fallen with margin: ROE went from 23.5% (FY2022) to 9.4% (FY2025). Leverage is not a constraint. The cash conversion cycle of about 137 days reflects the roughly 140 days of inventory the company holds to serve many small customers through distributors.
6.5 Interim update: 1H2026 (company investor conference, 23 September 2026)
First-half revenue rose 27.7% and net income 119.5%. Operating margin was flat, so the earnings jump came from below the operating line. S&P shows a trailing-twelve-month currency gain of TWD 26.3 million to June 2026, against a TWD 5.8 million loss in FY2025. Trailing-twelve-month figures to 30 June 2026: revenue TWD 1,921 million, net income TWD 156 million, diluted EPS TWD 4.61. Revenue for January–August 2026 was TWD 1,305 million, up 21.51%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Lines
| Product line (% of revenue) | FY2024 | 1H2025 | 2026 YTD |
|---|---|---|---|
UV absorbers and light stabilisers (%) | 52 | 56.9 | 60 |
Antioxidants (%) | 28 | 25.7 | 22.3 |
Photoinitiators (%) | 19 | 17 | 15.4 |
Flame retardants and other (%) | 1 | 0.4 | 1.6 |
Product Lines (FY2024–1H2026)
| Product line (TWD Mn, implied) | FY2024 | 1H2025 | 1H2026 |
|---|---|---|---|
UV absorbers and light stabilisers | 766 | 434 | 584 |
Antioxidants | 412 | 196 | 217 |
Photoinitiators | 280 | 130 | 150 |
Flame retardants and other | 15 | 3 | 16 |
Total consolidated revenue | 1,473 | 762 | 973 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (TWD Mn) | 1,497 | 1,598 | 1,262 | 1,473 | 1,711 |
Revenue growth (%) | 29.09 | 6.73 | -20.98 | 16.64 | 16.19 |
Cost of revenue (TWD Mn) | 1,151 | 1,173 | 911.68 | 1,056 | 1,318 |
Gross profit (TWD Mn) | 346.05 | 424.36 | 350.80 | 416.86 | 393.04 |
SG&A (TWD Mn) | 149.01 | 171.76 | 156.68 | 189.48 | 207.66 |
R&D expense (TWD Mn) | 20.86 | 42.59 | 61.41 | 29.20 | 31.06 |
Operating income (TWD Mn) | 176.51 | 210.00 | 132.71 | 197.72 | 154.56 |
EBITDA (TWD Mn) | 237.85 | 269.98 | 184.90 | 241.90 | 199.09 |
Currency gain or loss (TWD Mn) | -3.71 | 23.03 | 1.61 | 18.56 | -5.75 |
Pre-tax income (TWD Mn) | 173.68 | 249.62 | 155.68 | 213.17 | 149.07 |
Income tax (TWD Mn) | 42.91 | 53.42 | 35.44 | 51.80 | 42.72 |
Net income (TWD Mn) | 130.77 | 196.20 | 120.24 | 161.37 | 106.35 |
EPS basic (TWD) | 4.40 | 6.33 | 3.57 | 4.79 | 3.15 |
EPS diluted (TWD) | 4.36 | 6.26 | 3.54 | 4.76 | 3.14 |
Dividend per share (TWD) | 2.00 | 3.00 | 2.00 | 2.50 | 1.60 |
Gross margin (%) | 23.12 | 26.56 | 27.79 | 28.31 | 22.97 |
Operating margin (%) | 11.79 | 13.14 | 10.51 | 13.43 | 9.03 |
EBITDA margin (%) | 15.89 | 16.90 | 14.64 | 16.43 | 11.64 |
Net margin (%) | 8.73 | 12.28 | 9.52 | 10.96 | 6.22 |
Effective tax rate (%) | 24.71 | 21.40 | 22.76 | 24.30 | 28.66 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (TWD Mn) | 1,213 | 1,459 | 1,434 | 1,591 | 1,646 |
Cash and equivalents (TWD Mn) | 124.59 | 419.19 | 423.73 | 402.40 | 321.47 |
Cash and short-term investments (TWD Mn) | 143.19 | 424.75 | 433.63 | 452.04 | 336.11 |
Receivables (TWD Mn) | 210.10 | 194.84 | 172.77 | 199.03 | 260.87 |
Inventory (TWD Mn) | 407.42 | 387.34 | 421.55 | 477.42 | 502.31 |
Property, plant and equipment (TWD Mn) | 417.32 | 378.61 | 358.75 | 357.74 | 414.55 |
Total debt incl. leases (TWD Mn) | 216.42 | 154.83 | 125.37 | 153.91 | 118.48 |
Short-term debt incl. current portions (TWD Mn) | 62.17 | 24.38 | 20.01 | 20.38 | 37.71 |
Long-term debt incl. leases (TWD Mn) | 154.25 | 130.45 | 105.35 | 133.52 | 80.77 |
Net debt, negative = net cash (TWD Mn) | 73.23 | -269.92 | -308.26 | -298.14 | -217.63 |
Total liabilities (TWD Mn) | 545.00 | 455.70 | 413.62 | 466.86 | 504.68 |
Shareholders' equity (TWD Mn) | 667.67 | 1,003 | 1,020 | 1,124 | 1,141 |
Goodwill (TWD Mn) | 0 | 0 | 0 | 0 | 0 |
Other intangibles (TWD Mn) | 1.37 | 1.05 | 3.12 | 1.99 | 0.97 |
Working capital (TWD Mn) | 398.46 | 721.75 | 761.01 | 847.89 | 742.77 |
Book value per share (TWD) | 22.45 | 29.75 | 30.26 | 33.34 | 33.84 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (TWD Mn) | 296.94 | 262.92 | 150.06 | 142.83 | 129.39 |
Capital expenditure (TWD Mn) | 20.10 | 31.65 | 31.62 | 84.98 | 108.37 |
Free cash flow (TWD Mn) | 276.84 | 231.27 | 118.44 | 57.85 | 21.02 |
Dividends paid (TWD Mn) | 14.58 | 59.47 | 101.15 | 67.43 | 84.29 |
Share buybacks (TWD Mn) | 0 | 0 | 0 | 0 | 0 |
Share issuance (TWD Mn) | 0 | 186.47 | 0 | 0 | 0 |
Net debt issued or repaid (TWD Mn) | -233.96 | -62.16 | -29.70 | 13.80 | -35.30 |
Depreciation and amortisation (TWD Mn) | 68.33 | 67.35 | 59.82 | 51.84 | 52.03 |
Change in working capital (TWD Mn) | 139.03 | -20.47 | 3.44 | -46.88 | -19.26 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 21.43 | 23.48 | 11.88 | 15.05 | 9.39 |
ROA (%) | 9.23 | 9.83 | 5.73 | 8.17 | 5.97 |
ROIC (%) | 16.57 | 22.39 | 14.18 | 19.46 | 12.61 |
Current ratio (x) | 2.08 | 3.40 | 3.72 | 3.87 | 2.97 |
Quick ratio (x) | 0.95 | 2.06 | 2.17 | 2.21 | 1.58 |
Debt / equity (x) | 0.32 | 0.15 | 0.12 | 0.14 | 0.10 |
Net debt / EBITDA (x) | 0.31 | -1.00 | -1.67 | -1.23 | -1.09 |
Interest coverage, EBIT / interest (x) | 44.7 | 75.5 | 53.9 | 69.6 | 61.1 |
Asset turnover (x) | 1.25 | 1.20 | 0.87 | 0.97 | 1.06 |
Inventory turnover (x) | 2.81 | 2.95 | 2.25 | 2.35 | 2.69 |
Days sales outstanding (days) | 49 | 42 | 49 | 47 | 55 |
Days inventory (days) | 129 | 121 | 169 | 165 | 139 |
Days payable (days) | 60 | 41 | 60 | 52 | 58 |
Cash conversion cycle (days) | 119 | 122 | 158 | 161 | 137 |
Income Statement and Margin Analysis (%) (1H2025–1H2026)
| Metric | 1H2025 | 1H2026 |
|---|---|---|
Revenue (TWD Mn) | 762 | 973 |
Gross profit (TWD Mn) | — | 235 |
Gross margin (%) | — | 24.21 |
Operating income (TWD Mn) | — | 112 |
Operating margin (%) | 11.56 | 11.57 |
Net income (TWD Mn) | 41 | 90 |
EPS (TWD) | 1.21 | 2.68 |
Revenue by Region (%)
| Region (% of revenue) | FY2024 | 1H2026 |
|---|---|---|
Taiwan (%) | 11 | 8.6 |
Asia excluding Taiwan (%) | 52 | 56.5 |
of which China (%) | — | 43.6 |
of which other Asia (%) | — | 12.9 |
Americas / North America (%) | 27 | 26.2 |
Europe (%) | 8 | 8.7 |
“—” = not publicly disclosed.
Revenue by Region
| Region (TWD Mn, implied) | FY2024 | 1H2026 |
|---|---|---|
Taiwan | 162 | 84 |
Asia excluding Taiwan | 766 | 550 |
Americas / North America | 398 | 255 |
Europe | 118 | 85 |
Capital Markets Data (TWD) and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end adjusted close (TWD) | 44.27 | 36.20 | 43.27 | 56.05 | 60.54 |
Market capitalisation (TWD Mn) | 1,600 | 1,431 | 1,608 | 2,013 | 2,067 |
Enterprise value (TWD Mn) | 1,802 | 1,193 | 1,275 | 1,745 | 1,866 |
P/E (x) | 12.23 | 7.30 | 13.38 | 12.47 | 19.43 |
EV/EBITDA (x) | 7.58 | 4.42 | 6.90 | 7.21 | 9.37 |
EV/Sales (x) | 1.20 | 0.75 | 1.01 | 1.19 | 1.09 |
P/B (x) | 2.40 | 1.43 | 1.58 | 1.79 | 1.81 |
Dividend per share (TWD) | 2.00 | 3.00 | 2.00 | 2.50 | 1.60 |
Dividend yield (%) | 4.52 | 8.29 | 4.62 | 4.46 | 2.64 |
Payout ratio (%) | 11.15 | 30.31 | 84.12 | 41.79 | 79.26 |
Valuation Snapshot
| Metric | Value |
|---|---|
Market capitalisation (TWD Mn) | 3,827 |
Enterprise value (TWD Mn) | 3,641 |
Trailing P/E (x) | 24.63 |
EV/EBITDA (x) | 15.83 |
EV/Sales (x) | 1.90 |
P/B (x) | 3.23 |
Dividend yield (%) | 1.41 |
Beta, 5-year | 2.09 |
52-week price change, as of 24 Sep 2026 (%) | 97.02 |
50-day / 200-day moving average (TWD) | 110.58 / 102.44 |
20-day average volume (shares) | 261,424 |
Analyst Conclusions
Management guidance. For 2027: near double-digit revenue growth, gross margin held near the 2026 level if possible, and net profit growth driven by volume. New unit at 3% of revenue in 2027 and 8% in 2028. Patented products at 10–12% of revenue within five years. No 2026 full-year numeric guidance was given.
Consensus. None. On the eight-month run rate, FY2026 revenue should land close to TWD 2 billion; this is an analyst inference and not a company forecast.
Bull case
-
Volume momentum is broad. Every product line grew in 1H2026; eight-month revenue is up 21.5%; trailing EPS of TWD 4.61 already matches the FY2024 level.
-
The portfolio is moving up the value curve. Blue-light absorbers are in mass production, GA403 has EU food-contact clearance with China targeted for 2027, and three patents were granted in mid-2026.
-
Chitec is a rare non-China, Taiwan-based additive source with spare capacity for one to two years of growth, net cash, and a possible strategic investor.
Bear case
-
The quality of the 2026 earnings recovery is doubtful. Operating margin was flat at 11.57%; the EPS jump came from currency and a low base. Gross margin of 24.2% is still four points below FY2024.
-
China at 43.6% of sales is partly stocking ahead of a shipping scare. A reversal in 2027 would fall on a higher fixed-cost base (new warehouse, laboratory, owned head office).
-
At 24.6 times trailing earnings and 15.8 times EBITDA, with negative free cash flow, no analyst coverage, a beta above 2 and possible 24% dilution, the stock already prices in the blue-light and battery story.
Catalysts and things to watch over the next 12 months
-
3Q2026 results (about 13 November 2026): gross margin against 24.2%, and the currency line.
-
Monthly revenue through 4Q2026 and 1Q2027 for signs of China destocking.
-
Execution and pricing of the private placement, and the identity of any strategic investor.
-
First disclosed revenue from blue-light absorbers and from the Electronic and Battery Materials unit.
-
China food-contact approval for GA403.
-
Opening of the Shanghai application lab and completion of the Changbin laboratory.
-
Regulatory decisions on benzotriazole UV absorbers.
-
Photoinitiator pricing.
Analyst verdict. Chitec is a credible small specialist caught between two stories. The first is real. A 28-year-old additives house with regulatory files, patents and blue-chip approvals is selling record volumes, and customers want a supplier outside China. Revenue has grown at double-digit rates for two and a half years. The product news in 2026 (EFSA clearance for GA403, patents for R-455 and 9546, two blue-light products in production) is evidence of a working innovation pipeline.
The second story is less comfortable. Growth has come with lower margins. Gross margin fell from 28.3% to 23.0% in FY2025, and FY2025 net income was the weakest in five years on record sales. The 1H2026 rebound in EPS owes more to currency than to operations. The largest market, China, is also the one most distorted by temporary stocking and most exposed to local competitors. Free cash flow has turned negative as the company builds a warehouse, a laboratory and buys its head office. Reported R&D spending is modest for a business that sells differentiation.
The balance sheet removes any solvency concern, and management's targets (near double-digit growth in 2027, 3% then 8% of revenue from battery and electronic materials, 10–12% from patented products) are measurable. The issue is price. The shares have roughly doubled in a year to 24.6 times trailing earnings without analyst coverage, and a discounted private placement could add up to 24% more stock.
Our assessment: operationally improving, strategically well placed, financially sound, but with unproven margin recovery and a valuation that assumes it. Two numbers will settle the argument: gross margin returning toward 26–28%, and the first reported sales from blue-light and battery materials. Until those appear, the evidence supports a growing company more than a re-rated one.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Background | Tenure / notes |
|---|---|---|---|
Long Hsiao-Fen (龍筱芬) | Chairman and President | EMBA, National Taiwan Normal University; accounting studies, Essex County College, Newark, New Jersey | Chairman in all current sources; also director and GM of the Shanghai subsidiary since 15 December 2023 |
Lin Ting-Ting (林婷婷) | AVP Finance & Accounting; spokesperson | Accounting, National Taiwan University; NTU EMBA | Head of finance since 2003 (MarketScreener) |
Yang Hsiu-Fang (楊秀芳) | AVP Sales & Marketing; deputy spokesperson | Accounting, Soochow University | — |
Yao Sung-Fang (姚頌芳) | AVP Sales & Marketing (as introduced at the September 2026 conference) | — | — |
Wu Huang-Min (吳皇旻) | Head of R&D | MSc Chemistry, National Tsing Hua University | — |
Tsai Kuei-Ping (蔡貴平) | Senior Plant Director | Chemical Engineering and EMBA, National Tsing Hua University | — |
Lo Tang-Yu (羅棠榆) | Hsinchu Plant Director | MSc Chemical Engineering, NTUST | — |
Chu Te-Chang (曲德昌) | Special Assistant to the Chairman; director | Mathematics and Economics, University of Toronto; ex-Wedbush Securities risk analyst; ex-AIG investment analyst; CFA | First-degree relative of the chairman |
Hsieh Shang-Yu (謝尚祐) | Special Assistant to the Chairman | MSc, Institute of Nuclear Science, National Tsing Hua University | — |
Chung Cho-Chi (鍾卓冀) | Special Assistant to the Chairman; director | MSc Shipping Management, National Taiwan Ocean University; former supervisor of the company | — |
Long Hsiao-Fen | Chairman, representing Yi-De Specialty Chemical Investment Co., Ltd. | 2,393,797 (entity) | As above |
Chu Te-Chang | Director | 1,460,601 | As above |
Chung Cho-Chi | Director | 6,000 | As above |
Chen Ching-Ling (陳靖玲) | Independent director | 0 | Master of Accounting, University of Illinois; chairman of a financial advisory firm |
Chen Chih-Wei (陳致瑋) | Independent director | 0 | MA Administrative Management, California State University, Los Angeles |
Shao Chung-Yi (邵仲益) | Independent director | 0 | — |
Yeh Yu-Lin (葉玉琳) | Independent director | 0 | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares / lots | Stake (%) | Source |
|---|---|---|---|
Long Hsiao-Fen, personal | 2,973 lots | 8.82 | Fubon/MOPS, June 2026 |
Yi-De Specialty Chemical Investment Co., Ltd. (controlled by Long) | 2,394 lots | 7.10 | Fubon/MOPS; registry |
Chu Te-Chang | 1,460,601 shares | 4.33 | Registry |
All directors | 3,870 lots | 11.5 | Goodinfo, August 2026 |
Insiders, S&P definition | — | 18.39 | StockAnalysis |
Institutions, S&P definition | — | 2.46 | StockAnalysis |
Domestic individuals | 27,904 lots | 82.8 | Goodinfo, 2026 |
Domestic corporates | 4,300 lots | 12.8 | Goodinfo, 2026 |
Foreign investors | 1,512 lots | 4.48 (Goodinfo) or 6.18 (Cnyes) | Sources differ |
Competitive Landscape
Competitors by Segment
| Product line | Named competitors | Positioning relative to Chitec |
|---|---|---|
UV absorbers and HALS | BASF (Tinuvin, Chimassorb); Syensqo, formerly Solvay (Cyasorb); Clariant; Songwon; SI Group; ADEKA; Sabo; Rianlon; Everlight Chemical (Eversorb); Double Bond Chemical | Global majors hold formulation approvals and scale. Chinese producers lead on cost. Everlight and Double Bond are the closest Taiwanese peers |
Antioxidants | BASF (Irganox, Irgafos); Songwon; SI Group; ADEKA; Rianlon | A commodity market at the base. Chitec plays in niches (Revonox 501, 420V) |
Photoinitiators | IGM Resins; Tianjin Jiuri New Materials; Changzhou Tronly; Double Bond Chemical; Arkema (Sartomer) | Third-party research describes Chitec as one of five principal global suppliers alongside IGM and Chinese producers. It is the lowest-margin line |
Flame retardants | ICL; Lanxess; ADEKA; Clariant; Teijin (as customer and peer) | Chitec is sub-scale at 1–2% of revenue |
Peer Comparison FY2025
| Metric | Chitec (TTM to Jun 2026) | Everlight Chemical 1711.TW (TTM to Jun 2026) |
|---|---|---|
Revenue (TWD Mn) | 1,921 | 7,820 |
Revenue growth (%) | 27.94 | — |
Gross margin (%) | 22.60 | 20.2 |
Operating margin (%) | 9.31 | negative to break-even |
R&D intensity (%) | 1.77 | 4.8 |



